drugset
drugset / Trial / NCT07446049

A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression

NCT07446049 ↗

Phase 2 Not yet recruiting 180 enrolled Convalife (Shanghai) Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression

Timeline

Start
2026-05-01
Primary completion
2028-01-09
Completion
2028-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CVL237 Unknown 100 mg Oral
Subject CVL237 Unknown 200 mg Oral

Indications

No indication recorded.